|
|
|
|
|
|
|
|
abstract
Highlights
- •
- HSR are a common adverse event in patients rechallenged with carboplatin for ROC
- •
- Carboplatin-PLD is associated with a lower risk of developing HSR compared to other doublets
- •
- Several strategies have been developed to continue platinum-based therapy in these patients.
- •
- Cisplatin rechallenge in patients with carboplatin HSR is a safe and feasible approach.
- •
- In patients treated with cisplatin without a carboplatin-related HSR, a low rate of cisplatin-related HSR has been detected.
Hypersensitivity
reactions (HSR) are frequently reported in patients rechallenged with
carboplatin for recurrent ovarian cancer (ROC) and represent a critical
issue, since discontinuation of the platinum-based therapy could affect
prognosis. Several strategies to allow platinum rechallenge have been
described, with controversial outcomes. The aim of this study is to
illustrate a 10-year experience with cisplatin in patients with a
previous HSR to carboplatin or at risk for allergy. A retrospective
review of all patients with platinum sensitive ROC retreated with
carboplatin was performed between January 2007 and May 2016 at the
Istituto Nazionale Tumori, Fondazione “G. Pascale”, Naples. Among 183
patients, 49 (26.8%) presented HSR to carboplatin, mainly during second
line therapy. Mean number of cycles before HSR was 8 (range 3–17). G2,
G3 and G4 reaction were detected in 83%, 15% and 2% of patients,
respectively. In a multivariate analysis including age, hystotype, BRCA
status, previous known HSR, and combination drug administered, only the
type of carboplatin-based doublet used as 2nd line therapy was found to
significantly affect HSR development, with a protective effect of PLD
(pegylated liposomal doxorubicin) (p = 0.014, OR = 0.027). Thirty seven
patients (77%) with a previous HSR to carboplatin were rechallenged with
cisplatin. Treatment was generally well tolerated. 5 patients (13.1%)
experienced mild HSR to cisplatin, successfully managed in all cases. 14
patients were treated with cisplatin even without a carboplatin-related
HSR due to other allergies. Among these, only one developed HSR (7.1%).
Cisplatin rechallenge is a feasible approach in patients experiencing
HSR to carboplatin to maintain the beneficial effect of platinum while
reducing hypersensitivity-related risks.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.